<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AGGRENOX - aspirin and dipyridamole capsule </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Aggrenox Capsules safely and effectively. See full prescribing information for Aggrenox Capsules.<br><br> 
	AGGRENOX® (aspirin/extended-release dipyridamole) Capsules<br> 
	Initial U.S. Approval: 1999</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc"><li>AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients who have had transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the brain or completed <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> due to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> <a href="#Section_1">(1)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>One capsule twice daily (morning and evening) with or without food <a href="#Section_2">(2)</a>
</li>
<li>In case of intolerable <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning; resume BID dosing within one week <a href="#Section_2">(2)</a>
</li>
<li>Do not chew capsule <a href="#Section_2">(2)</a>
</li>
<li>
<span class="Bold"><span class="Emphasis">Not interchangeable with the individual components of aspirin and dipyridamole tablets </span></span><a href="#Section_2">(2)</a>
</li>
<li>Dispense in this unit-of-use container <a href="#Section_16">(16)</a>
</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Capsule: 25 mg aspirin/200 mg extended-release dipyridamole <a href="#Section_3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any product ingredients <a href="#Section_4.1">(4.1)</a>
</li>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to NSAIDs <a href="#Section_4.2">(4.2)</a>
</li>
<li>Patients with the syndrome of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span> <a href="#Section_4.2">(4.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>The risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is increased, especially in patients who are heavy alcohol users, have a history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, or have coagulation abnormalities due to liver disease or <span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">vitamin K deficiency</span> <a href="#Section_5.1">(5.1)</a>
</li>
<li>As with other antiplatelets, there is a risk of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> <a href="#Section_5.1">(5.1)</a>
</li>
<li>Avoid use in patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <a href="#Section_5.2">(5.2</a>, <a href="#Section_5.3">5.3)</a>
</li>
<li>Can cause fetal harm when administered to a pregnant woman, especially in the third trimester <a href="#Section_5.4">(5.4)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>The most frequently reported adverse reactions (&gt;10% and greater than placebo) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <a href="#Section_6">(6)</a>
</li></ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Co-administration with anti-coagulants or NSAIDS can increase risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#Section_7.4">(7.4</a>, <a href="#Section_7.10">7.10</a>)</li>
<li>Decreased renal function can occur with co-administration with NSAIDS <a href="#Section_7.10">(7.10)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc"><li>Pregnancy Category D <a href="#Section_8.1">(8.1)</a>
</li></ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling</span></span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Alternative Regimen in Case of Intolerable <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span></a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1  Hypersensitivity</a></h2>
<h2><a href="#section-4.2" class="toc">4.2  Allergy</a></h2>
<h2><a href="#section-4.3" class="toc">4.3  Reye Syndrome</a></h2>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Renal Failure</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Hepatic Insufficiency</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Pregnancy</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Coronary Artery Disease</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Hypotension</a></h2>
<h2><a href="#section-5.7" class="toc">5.7  General</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Adenosine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Angiotensin Converting Enzyme (ACE) Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Acetazolamide</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Anticoagulant Therapy (heparin and warfarin)</a></h2>
<h2><a href="#section-7.5" class="toc">7.5  Anticonvulsants</a></h2>
<h2><a href="#section-7.6" class="toc">7.6  Beta Blockers</a></h2>
<h2><a href="#section-7.7" class="toc">7.7  Cholinesterase Inhibitors</a></h2>
<h2><a href="#section-7.8" class="toc">7.8  Diuretics</a></h2>
<h2><a href="#section-7.9" class="toc">7.9  Methotrexate</a></h2>
<h2><a href="#section-7.10" class="toc">7.10  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2>
<h2><a href="#section-7.11" class="toc">7.11  Oral Hypoglycemics </a></h2>
<h2><a href="#section-7.12" class="toc">7.12  Uricosuric Agents (probenecid and sulfinpyrazone)</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2  Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5  Geriatric Use </a></h2>
<h2><a href="#section-8.6" class="toc">8.6  Patients with Severe Hepatic or Severe Renal Dysfunction</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h2><a href="#section-10.1" class="toc"></a></h2>
<h2><a href="#section-10.2" class="toc"></a></h2>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"></a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-15.2" class="toc">17.2  Pregnancy</a></h2>
<h2><a href="#section-15.3" class="toc">17.3  Headaches</a></h2>
<h2><a href="#section-15.4" class="toc">17.4  Dosage and Administration</a></h2>
<h2><a href="#section-15.5" class="toc">17.5  Storage</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">AGGRENOX is indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients who have had transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the brain or completed <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> due to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">AGGRENOX is not interchangeable with the individual components of aspirin and dipyridamole tablets. </span></span></p>
<p>The recommended dose of AGGRENOX is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. AGGRENOX can be administered with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Alternative Regimen in Case of Intolerable <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span></h2>
<p class="First">In the event of intolerable <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">25 mg/200 mg capsules with a red cap and an ivory-colored body, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1  Hypersensitivity</h2>
<p class="First">AGGRENOX is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the product components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2  Allergy</h2>
<p class="First">Aspirin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to nonsteroidal anti-inflammatory drug products and in patients with the syndrome of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>. Aspirin may cause severe <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3  Reye Syndrome</h2>
<p class="First">Do not use aspirin in children or teenagers with <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> because of the risk of Reye syndrome.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial Hemorrhage</span></span></span><br>
								In ESPS2 the incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> was 0.6% in the AGGRENOX group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups.</p>
<p><span class="Italics"><span class="Emphasis">Coagulation Abnormalities</span></span><br>Even low doses of aspirin can inhibit platelet function leading to an increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. This can adversely affect patients with inherited or acquired (liver disease or <span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">vitamin K deficiency</span>) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders [<span class="Italics"><span class="Emphasis">see Drug Interactions <a href="#Section_7.4">(7.4)</a></span></span>].</p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal (GI) Side Effects</span></span><br>GI side effects include <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and gross GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Although minor upper GI symptoms, such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur.</p>
<p>In ESPS2 the incidence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> was 4.1% in the AGGRENOX group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups. </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span></span></span><br>
								Avoid using aspirin in patients with a history of active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, which can cause gastric mucosal irritation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Italics"><span class="Emphasis">Alcohol Warning</span></span><br>
								Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risks involved with chronic, heavy alcohol use while taking aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Renal Failure</h2>
<p class="First">Avoid aspirin in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (glomerular filtration rate less than 10 mL/minute) [<span class="Italics"><span class="Emphasis">see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Hepatic Insufficiency</h2>
<p class="First">Elevations of hepatic enzymes and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported in association with dipyridamole administration [<span class="Italics"><span class="Emphasis">see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Pregnancy</h2>
<p class="First">Because AGGRENOX contains aspirin, AGGRENOX can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> in premature infants, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid AGGRENOX in the third trimester of pregnancy [<span class="Italics"><span class="Emphasis">see Use in Specific Populations <a href="#Section_8.1">(8.1)</a></span></span>].</p>
<p>Aspirin has been shown to be teratogenic in rats (<span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span> and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m<span class="Sup">2</span> basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of AGGRENOX. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m<span class="Sup">2</span> basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of AGGRENOX in pregnant women. If AGGRENOX is used during pregnancy, or if the patient becomes pregnant while taking AGGRENOX, inform the patient of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Coronary Artery Disease</h2>
<p class="First">Dipyridamole has a vasodilatory effect. <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> may be precipitated or aggravated in patients with underlying <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> who are receiving dipyridamole.</p>
<p>For <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA patients for whom aspirin is indicated to prevent recurrent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) or <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, the aspirin in this product may not provide adequate treatment for the cardiac indications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Hypotension</h2>
<p class="First">Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7  General</h2>
<p class="First">AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> [<span class="Italics"><span class="Emphasis">see Contraindications <a href="#Section_4.1">(4.1)</a></span></span>].</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> [<span class="Italics"><span class="Emphasis">see Contraindications <a href="#Section_4.2">(4.2)</a></span></span>].</li>
<li>Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span></span>].</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The efficacy and safety of AGGRENOX was established in the European <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo controlled study that evaluated 6602 patients over the age of 18 years who had a previous <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14">(14)</a></span></span>]; primary endpoints included <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (fatal or nonfatal) and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from all causes.</p>
<p>This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> or transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the brain within three months prior to randomization.</p>
<p>Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety.</p>
<a name="t1"></a><table cellpadding="1" cellspacing="1" width="100%">
<caption><span>Table 1   Incidence of Adverse Events in ESPS2*</span></caption>
<colgroup>
<col align="left" width="40%">
<col align="left" width="15%">
<col align="left" width="15%">
<col align="left" width="15%">
<col align="left" width="15%">
</colgroup>
<thead>
<tr class="First">
<th align="left"> </th>
<th align="left" colspan="8">Individual Treatment Group</th>
</tr>
<tr class="Last">
<th class="Toprule" align="left">Body System/Preferred Term</th>
<th class="Toprule" align="left">AGGRENOX</th>
<th class="Toprule" align="left">ER-DP Alone</th>
<th class="Toprule" align="left">ASA Alone</th>
<th class="Toprule" align="left">Placebo</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5">* Reported by ≥1% of patients during AGGRENOX treatment where the incidence was greater than in those treated with placebo.</td></tr>
<tr class="Last"><td align="left" colspan="5">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID<br>
											          NOS = not otherwise specified.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold"><span class="Emphasis">Total Number of Patients</span></span></td>
<td align="left">1650</td>
<td align="left">1654</td>
<td align="left">1649</td>
<td align="left">1649</td>
</tr>
<tr>
<td class="Toprule" align="left"><span class="Bold"><span class="Emphasis">Total Number (%) of Patients With at<br>   Least One On-Treatment Adverse<br>   Event</span></span></td>
<td class="Toprule" align="left">
<br><br>1319  (80%)</td>
<td class="Toprule" align="left">
<br><br>1305  (79%)</td>
<td class="Toprule" align="left">
<br><br>1323  (80%)</td>
<td class="Toprule" align="left">
<br><br>1304  (79%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td></tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule" align="left">647  (39%)</td>
<td class="Toprule" align="left">634  (38%)</td>
<td class="Toprule" align="left">558  (34%)</td>
<td class="Toprule" align="left">543  (33%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td class="Toprule" align="left">28   (2%)</td>
<td class="Toprule" align="left">15   (1%)</td>
<td class="Toprule" align="left">28   (2%)</td>
<td class="Toprule" align="left">26   (2%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Gastrointestinal System Disorders</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Toprule" align="left">303   (18%)</td>
<td class="Toprule" align="left">288   (17%)</td>
<td class="Toprule" align="left">299   (18%)</td>
<td class="Toprule" align="left">275   (17%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Toprule" align="left">289   (18%)</td>
<td class="Toprule" align="left">255   (15%)</td>
<td class="Toprule" align="left">262   (16%)</td>
<td class="Toprule" align="left">239   (14%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule" align="left">264   (16%)</td>
<td class="Toprule" align="left">254   (15%)</td>
<td class="Toprule" align="left">210   (13%)</td>
<td class="Toprule" align="left">232   (14%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Toprule" align="left">210   (13%)</td>
<td class="Toprule" align="left">257   (16%)</td>
<td class="Toprule" align="left">112   (7%)</td>
<td class="Toprule" align="left">161   (10%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Toprule" align="left">138   (8%)</td>
<td class="Toprule" align="left">129   (8%)</td>
<td class="Toprule" align="left">101   (6%)</td>
<td class="Toprule" align="left">118   (7%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Hemorrhage Rectum</span></td>
<td class="Toprule" align="left">26   (2%)</td>
<td class="Toprule" align="left">22   (1%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">Melena</span></td>
<td class="Toprule" align="left">31   (2%)</td>
<td class="Toprule" align="left">10   (1%)</td>
<td class="Toprule" align="left">20   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
<td class="Toprule" align="left">10   (1%)</td>
<td class="Toprule" align="left">10   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI Hemorrhage</span></td>
<td class="Toprule" align="left">20   (1%)</td>
<td class="Toprule" align="left">5    (0%)</td>
<td class="Toprule" align="left">15   (1%)</td>
<td class="Toprule" align="left">7    (0%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Body as a Whole - General Disorders</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Toprule" align="left">105  (6%)</td>
<td class="Toprule" align="left">88   (5%)</td>
<td class="Toprule" align="left">103  (6%)</td>
<td class="Toprule" align="left">99   (6%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Toprule" align="left">95   (6%)</td>
<td class="Toprule" align="left">93   (6%)</td>
<td class="Toprule" align="left">97   (6%)</td>
<td class="Toprule" align="left">90   (5%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Toprule" align="left">76   (5%)</td>
<td class="Toprule" align="left">77   (5%)</td>
<td class="Toprule" align="left">74   (4%)</td>
<td class="Toprule" align="left">65   (4%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></td>
<td class="Toprule" align="left">42   (3%)</td>
<td class="Toprule" align="left">24   (1%)</td>
<td class="Toprule" align="left">51   (3%)</td>
<td class="Toprule" align="left">37   (2%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Toprule" align="left">27   (2%)</td>
<td class="Toprule" align="left">23   (1%)</td>
<td class="Toprule" align="left">26   (2%)</td>
<td class="Toprule" align="left">22   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Toprule" align="left">29   (2%)</td>
<td class="Toprule" align="left">19   (1%)</td>
<td class="Toprule" align="left">17   (1%)</td>
<td class="Toprule" align="left">18   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td class="Toprule" align="left">17   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">8   (0%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Psychiatric Disorders</span></span></td></tr>
<tr>
<td class="Toprule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Toprule" align="left">39   (2%)</td>
<td class="Toprule" align="left">40   (2%)</td>
<td class="Toprule" align="left">57   (3%)</td>
<td class="Toprule" align="left">34   (2%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Toprule" align="left">18   (1%)</td>
<td class="Toprule" align="left">9   (1%)</td>
<td class="Toprule" align="left">22   (1%)</td>
<td class="Toprule" align="left">15   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Toprule" align="left">19   (1%)</td>
<td class="Toprule" align="left">17   (1%)</td>
<td class="Toprule" align="left">10   (1%)</td>
<td class="Toprule" align="left">15   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Toprule" align="left">20   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
<td class="Toprule" align="left">18   (1%)</td>
<td class="Toprule" align="left">9   (1%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Musculoskeletal System Disorders</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Toprule" align="left">91   (6%)</td>
<td class="Toprule" align="left">75   (5%)</td>
<td class="Toprule" align="left">91   (6%)</td>
<td class="Toprule" align="left">76   (5%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></td>
<td class="Toprule" align="left">34   (2%)</td>
<td class="Toprule" align="left">25   (2%)</td>
<td class="Toprule" align="left">17   (1%)</td>
<td class="Toprule" align="left">19   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span></td>
<td class="Toprule" align="left">18   (1%)</td>
<td class="Toprule" align="left">22   (1%)</td>
<td class="Toprule" align="left">13   (1%)</td>
<td class="Toprule" align="left">14   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Toprule" align="left">20   (1%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">11   (1%)</td>
<td class="Toprule" align="left">11   (1%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></span></td></tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td class="Toprule" align="left">25   (2%)</td>
<td class="Toprule" align="left">18   (1%)</td>
<td class="Toprule" align="left">32   (2%)</td>
<td class="Toprule" align="left">21   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   Upper Respiratory Tract<br>   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">9   (1%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">14   (1%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General</span></span></td></tr>
<tr>
<td class="Toprule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></td>
<td class="Toprule" align="left">26   (2%)</td>
<td class="Toprule" align="left">17   (1%)</td>
<td class="Toprule" align="left">30   (2%)</td>
<td class="Toprule" align="left">25   (2%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></span></td></tr>
<tr>
<td class="Toprule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage NOS</span></td>
<td class="Toprule" align="left">52   (3%)</td>
<td class="Toprule" align="left">24   (1%)</td>
<td class="Toprule" align="left">46   (3%)</td>
<td class="Toprule" align="left">24   (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Toprule" align="left">39   (2%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">45   (3%)</td>
<td class="Toprule" align="left">25   (2%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span></td>
<td class="Toprule" align="left">23   (1%)</td>
<td class="Toprule" align="left">8    (0%)</td>
<td class="Toprule" align="left">9    (1%)</td>
<td class="Toprule" align="left">7    (0%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Neoplasm</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   Neoplasm NOS</td>
<td class="Toprule" align="left">28   (2%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">23   (1%)</td>
<td class="Toprule" align="left">20   (1%)</td>
</tr>
<tr><td class="Toprule" align="left" colspan="9"><span class="Bold"><span class="Emphasis">Red Blood Cell Disorders</span></span></td></tr>
<tr class="Last">
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Toprule" align="left">27   (2%)</td>
<td class="Toprule" align="left">16   (1%)</td>
<td class="Toprule" align="left">19   (1%)</td>
<td class="Toprule" align="left">9   (1%)</td>
</tr>
</tbody>
</table>
<p>Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2)</p>
<a name="t2"></a><table cellpadding="1" cellspacing="1" width="100%">
<caption><span>Table 2   Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of ≥1% in the AGGRENOX Group</span></caption>
<colgroup>
<col align="left" width="40%">
<col align="left" width="15%">
<col align="left" width="15%">
<col align="left" width="15%">
<col align="left" width="15%">
</colgroup>
<thead>
<tr class="First">
<th align="right"> </th>
<th align="center" colspan="4">Treatment Groups</th>
</tr>
<tr class="Last">
<th align="right"> </th>
<th class="Toprule" align="left">AGGRENOX</th>
<th class="Toprule" align="left">ER-DP</th>
<th class="Toprule" align="left">ASA</th>
<th class="Toprule" align="left">Placebo</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID	</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Bold"><span class="Emphasis">Total Number of Patients</span></span></td>
<td align="left">1650</td>
<td align="left">1654</td>
<td align="left">1649</td>
<td align="left">1649</td>
</tr>
<tr>
<td class="Toprule" align="left"><span class="Bold"><span class="Emphasis">Patients with at least one Adverse Event<br>that led to treatment discontinuation</span></span></td>
<td class="Toprule" align="left">
<br>417  (25%)</td>
<td class="Toprule" align="left">
<br>419  (25%)</td>
<td class="Toprule" align="left">
<br>318  (19%)</td>
<td class="Toprule" align="left">
<br>352  (21%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule" align="left">165  (10%)</td>
<td class="Toprule" align="left">166  (10%)</td>
<td class="Toprule" align="left">57  (3%)</td>
<td class="Toprule" align="left">69  (4%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Toprule" align="left">85  (5%)</td>
<td class="Toprule" align="left">97  (6%)</td>
<td class="Toprule" align="left">69  (4%)</td>
<td class="Toprule" align="left">68  (4%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule" align="left">91  (6%)</td>
<td class="Toprule" align="left">95  (6%)</td>
<td class="Toprule" align="left">51  (3%)</td>
<td class="Toprule" align="left">53  (3%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Toprule" align="left">74  (4%)</td>
<td class="Toprule" align="left">64  (4%)</td>
<td class="Toprule" align="left">56  (3%)</td>
<td class="Toprule" align="left">52  (3%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Toprule" align="left">59  (4%)</td>
<td class="Toprule" align="left">61  (4%)</td>
<td class="Toprule" align="left">49  (3%)</td>
<td class="Toprule" align="left">46  (3%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Toprule" align="left">53  (3%)</td>
<td class="Toprule" align="left">52  (3%)</td>
<td class="Toprule" align="left">28  (2%)</td>
<td class="Toprule" align="left">24  (1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Toprule" align="left">35  (2%)</td>
<td class="Toprule" align="left">41  (2%)</td>
<td class="Toprule" align="left">9  (&lt;1%)</td>
<td class="Toprule" align="left">16  (&lt;1%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td class="Toprule" align="left">39  (2%)</td>
<td class="Toprule" align="left">48  (3%)</td>
<td class="Toprule" align="left">57  (3%)</td>
<td class="Toprule" align="left">73  (4%)</td>
</tr>
<tr>
<td class="Toprule" align="left">   Transient Ischemic Attack</td>
<td class="Toprule" align="left">35  (2%)</td>
<td class="Toprule" align="left">40  (2%)</td>
<td class="Toprule" align="left">26  (2%)</td>
<td class="Toprule" align="left">48  (3%)</td>
</tr>
<tr class="Last">
<td class="Toprule" align="left">   <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span></td>
<td class="Toprule" align="left">23  (1%)</td>
<td class="Toprule" align="left">20  (1%)</td>
<td class="Toprule" align="left">16  (&lt;1%)</td>
<td class="Toprule" align="left">26  (2%)</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was most notable in the first month of treatment.</p>
<p><span class="Italics"><span class="Emphasis">Other Adverse Events</span></span><br>
Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below.</p>
<p><span class="Italics"><span class="Emphasis">Body as a Whole</span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular</span></span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p><span class="Italics"><span class="Emphasis">Central Nervous System</span></span>: <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span></p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal</span></span>: <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span>, ulceration and perforation</p>
<p><span class="Italics"><span class="Emphasis">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span></span></span>: <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>. Patients with high frequency <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> may have difficulty perceiving <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. In these patients, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> cannot be used as a clinical indicator of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span></p>
<p><span class="Italics"><span class="Emphasis">Heart Rate and Rhythm Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span></p>
<p><span class="Italics"><span class="Emphasis">Liver and Biliary System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span></p>
<p><span class="Italics"><span class="Emphasis">Metabolic and Nutritional Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Italics"><span class="Emphasis">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></span>: <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span> </p>
<p><span class="Italics"><span class="Emphasis">Psychiatric Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p>
<p><span class="Italics"><span class="Emphasis">Reproductive</span></span>: <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine hemorrhage</span></p>
<p><span class="Italics"><span class="Emphasis">Respiratory</span></span>: <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span></p>
<p><span class="Italics"><span class="Emphasis">Special Senses Other Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Taste loss</span> </p>
<p><span class="Italics"><span class="Emphasis">Skin and Appendages Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> </p>
<p><span class="Italics"><span class="Emphasis">Urogenital</span></span>: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> and failure, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span></p>
<p><span class="Italics"><span class="Emphasis">Vascular (Extracardiac) Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p>
<p><span class="Italics"><span class="Emphasis">Laboratory Changes</span></span><br>
Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x10<span class="Sup">6</span>/mm<span class="Sup">3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Post-Marketing Experience</h2>
<p class="First">The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX.</p>
<p><span class="Italics"><span class="Emphasis">Body as a Whole</span></span>: <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular</span></span>: <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span> </p>
<p><span class="Italics"><span class="Emphasis">Central Nervous System</span></span>: <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Cerebral edema</span> </p>
<p><span class="Italics"><span class="Emphasis">Fluid and Electrolyte</span></span>: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> </p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal</span></span>: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, Reye syndrome, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span> </p>
<p><span class="Italics"><span class="Emphasis">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span></span></span>: <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> </p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>  </p>
<p><span class="Italics"><span class="Emphasis">Liver and Biliary System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> </p>
<p><span class="Italics"><span class="Emphasis">Musculoskeletal</span></span>: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> </p>
<p><span class="Italics"><span class="Emphasis">Metabolic and Nutritional Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>  </p>
<p><span class="Italics"><span class="Emphasis">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></span>: Prolongation of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> </p>
<p><span class="Italics"><span class="Emphasis">Reproductive</span></span>: <span class="product-label-link" type="condition" conceptid="432695" conceptname="Post-term pregnancy">Prolonged pregnancy</span> and labor, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, lower birth weight infants, antepartum and postpartum <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </p>
<p><span class="Italics"><span class="Emphasis">Respiratory</span></span>: <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> </p>
<p><span class="Italics"><span class="Emphasis">Skin and Appendages Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, skin <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> such as <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> </p>
<p><span class="Italics"><span class="Emphasis">Urogenital</span></span>: Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> </p>
<p><span class="Italics"><span class="Emphasis">Vascular (Extracardiac Disorders)</span></span>: <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">Allergic vasculitis</span></p>
<p><span class="Italics"><span class="Emphasis">Other adverse events</span></span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">No pharmacokinetic drug-drug interaction studies were conducted with AGGRENOX capsules. The following information was obtained from the literature.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Adenosine</h2>
<p class="First">Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Angiotensin Converting Enzyme (ACE) Inhibitors</h2>
<p class="First">Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremic</span> and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Acetazolamide</h2>
<p class="First">Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Anticoagulant Therapy (heparin and warfarin)</h2>
<p class="First">Patients on anticoagulation therapy are at increased risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> because of drug-drug interactions and effects on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and the <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. Aspirin can increase the anticoagulant activity of heparin, increasing <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5  Anticonvulsants</h2>
<p class="First">Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6  Beta Blockers</h2>
<p class="First">The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7  Cholinesterase Inhibitors</h2>
<p class="First">Dipyridamole may counteract the anticholinesterase effect of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors, thereby potentially aggravating <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8  Diuretics</h2>
<p class="First">The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.9"></a><a name="section-7.9"></a><p></p>
<h2>7.9  Methotrexate</h2>
<p class="First">Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.10"></a><a name="section-7.10"></a><p></p>
<h2>7.10  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class="First">The concurrent use of aspirin with other NSAIDs may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or lead to decreased renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.11"></a><a name="section-7.11"></a><p></p>
<h2>7.11  Oral Hypoglycemics </h2>
<p class="First">Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.12"></a><a name="section-7.12"></a><p></p>
<h2>7.12  Uricosuric Agents (probenecid and sulfinpyrazone)</h2>
<p class="First">Salicylates antagonize the uricosuric action of uricosuric agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Teratogenic Effects, Pregnancy Category D.</span></span> [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2  Labor and Delivery</h2>
<p class="First">Aspirin can result in excessive blood loss at delivery as well as prolonged gestation and <span class="product-label-link" type="condition" conceptid="434714" conceptname="Prolonged second stage of labor">prolonged labor</span>. Because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span></span>], avoid AGGRENOX in the third trimester of pregnancy and during labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">Both dipyridamole and aspirin are excreted in human milk. Exercise caution when AGGRENOX capsules are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety and effectiveness of AGGRENOX in pediatric patients have not been studied. Due to the aspirin component, use of this product in the pediatric population is not recommended [<span class="Italics"><span class="Emphasis">see Contraindications <a href="#Section_4.3">(4.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5  Geriatric Use </h2>
<p class="First">Of the total number of subjects in ESPS2, 61 percent were 65 and over, while 27 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6  Patients with Severe Hepatic or Severe Renal Dysfunction</h2>
<p class="First">AGGRENOX has not been studied in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Avoid using aspirin containing products, such as Aggrenox in patients with severe hepatic or severe renal (glomerular filtration rate &lt; 10 mL/min) dysfunction [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.2">(5.2</a>, <a href="#Section_5.3">5.3)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">Because of the dose ratio of dipyridamole to aspirin, overdosage of AGGRENOX is likely to be dominated by signs and symptoms of dipyridamole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In case of real or suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential.</p>
<p>Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, feeling of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may occur. A <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> might also be observed.</p>
<p>Salicylate toxicity may result from acute ingestion (<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>) or chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Severity of aspirin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is determined by measuring the blood salicylate level. The early signs of salicylic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (<span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>), including <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> (ringing in the ears), occur at plasma concentrations approaching 200 µg/mL. In severe cases, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> are the major immediate threats to life. Plasma concentrations of aspirin above 300 µg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 µg/mL. A single lethal dose of aspirin in adults is not known with certainty but <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may be expected at 30 g. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists primarily of supporting vital functions, increasing drug elimination, and correcting acid-base disturbances. Consider gastric emptying and/or lavage as soon as possible after ingestion, even if the patient has <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> spontaneously. After lavage and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, administration of activated charcoal as a slurry may be beneficial if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and lavage. Follow acid-base status closely with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance. Administer replacement fluid intravenously and augment with correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Treatment may require the use of a vasopressor. Infusion of glucose may be required to control <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Plasma electrolytes and pH should be monitored serially to promote alkaline <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> of salicylate if renal function is normal. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in cases of life-threatening <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, dialysis is usually required to treat salicylic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, however since dipyridamole is highly protein bound, dialysis is not likely to remove dipyridamole. Exchange transfusion may be indicated in infants and young children.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">AGGRENOX is a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release sugar-coated tablet. In addition, each capsule contains the following inactive ingredients: acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide and triacetin.</p>
<p>Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide and water.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_11.1"></a><a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="Emphasis">Dipyridamole</span></span><br>
								Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-<span class="Italics"><span class="Emphasis">d</span></span>]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:</p>
<p><img alt="Structural formula of Dipyridamole." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5&amp;name=aggrenox%20struct1.jpg"></p>
<p>Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_11.2"></a><a name="section-10.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="Emphasis">Aspirin</span></span><br>
								The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-, and has the following structural formula:</p>
<p><img alt="Structural formula of benzoic acid." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5&amp;name=aggrenox%20struct2.jpg"></p>
<p>Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and aspirin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.1.1"></a><a name="section-11.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Dipyridamole</span></span><br>
										Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes <span class="Italics"><span class="Emphasis">in vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span>; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5–1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A<span class="Sub">2</span>-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). </p>
<p>Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.1.2"></a><a name="section-11.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Aspirin</span></span><br>
										Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A<span class="Sub">2</span>, a powerful inducer of platelet aggregation and <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics </h2>
<p class="First">The effect of either agent on the other's inhibition of platelet reactivity has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their co-administration as AGGRENOX. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-11.3.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Dipyridamole</span></span><br><span class="Underline"><span class="Emphasis">Absorption</span></span><br>
										Peak plasma levels of dipyridamole are achieved 2 hours (range 1–6 hours) after administration of a daily dose of 400 mg AGGRENOX (given as 200 mg BID). The peak plasma concentration at steady-state is 1.98 µg/mL (1.01–3.99 µg/mL) and the steady-state trough concentration is 0.53 µg/mL (0.18–1.01 µg/mL).</p>
<p><span class="Underline"><span class="Emphasis">Effect of Food</span></span><br>
										When AGGRENOX capsules were taken with a high fat meal, dipyridamole peak plasma levels (C<span class="Sub">max</span>) and total absorption (AUC) were decreased at steady-state by 20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.</p>
<p><span class="Underline"><span class="Emphasis">Distribution</span></span><br>
										Dipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.</p>
<p><span class="Underline"><span class="Emphasis">Metabolism and Elimination</span></span><br>
Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase λ<span class="Sub">z</span> with a half-life of about 15.5 hours. Due to the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with AGGRENOX which, in Trial 9.123 was 13.6 hours.</p>
<p><span class="Underline"><span class="Emphasis">Special Populations</span></span><br></p>
<p><span class="Italics"><span class="Emphasis">Geriatric Patients</span></span>: In ESPS2 [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14">(14)</a></span></span>], plasma concentrations (determined as AUC) of dipyridamole in healthy elderly subjects (&gt;65 years) were about 40% higher than in subjects younger than 55 years receiving treatment with AGGRENOX. </p>
<p><span class="Italics"><span class="Emphasis">Hepatic Dysfunction</span></span>: No study has been conducted with AGGRENOX in patients with hepatic dysfunction.</p>
<p>In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> showed no change in plasma concentrations of dipyridamole but showed an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
<p><span class="Italics"><span class="Emphasis">Renal Dysfunction</span></span>: No study has been conducted with AGGRENOX in patients with renal dysfunction.</p>
<p>In ESPS2 patients [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14">(14)</a></span></span>], with creatinine clearances ranging from about 15 mL/min to &gt;100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite if data were corrected for differences in age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.2"></a><a name="section-11.3.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Aspirin</span></span><br><span class="Underline"><span class="Emphasis">Absorption</span></span><br>
										Peak plasma levels of aspirin are achieved 0.63 hours (0.5–1 hour) after administration of a 50 mg aspirin daily dose from AGGRENOX (given as 25 mg BID). The peak plasma concentration at steady-state is 319 ng/mL (175–463 ng/mL). Aspirin undergoes moderate hydrolysis to salicylic acid in the liver and the gastrointestinal wall, with 50%–75% of an administered dose reaching the systemic circulation as intact aspirin.</p>
<p><span class="Underline"><span class="Emphasis">Effect of Food</span></span><br>
										When AGGRENOX capsules were taken with a high fat meal, there was no difference for aspirin in AUC at steady-state, and the approximately 50% decrease in C<span class="Sub">max</span> was not considered clinically relevant based on a similar degree of cyclooxygenase inhibition comparing the fed and fasted state.</p>
<p><span class="Underline"><span class="Emphasis">Distribution</span></span><br>
										Aspirin is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration-dependent (nonlinear). At low concentrations (&lt;100 µg/mL), approximately 90% of salicylic acid is bound to albumin. Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and fetal tissues. Early signs of salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (<span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>), including <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> (ringing in the ears), occur at plasma concentrations approximating 200 µg/mL [<span class="Italics"><span class="Emphasis">see Adverse Reactions <a href="#Section_6">(6)</a> and Overdosage <a href="#Section_10">(10)</a></span></span>].</p>
<p><span class="Underline"><span class="Emphasis">Metabolism and Elimination</span></span><br>
										Aspirin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 20 minutes. Plasma levels of aspirin are essentially undetectable 2–2.5 hours after dosing and peak salicylic acid concentrations occur 1 hour (range: 0.5–2 hours) after administration of aspirin. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses (10–20 g), the plasma half-life may be increased to over 20 hours.</p>
<p>The elimination of acetylsalicylic acid follows first-order kinetics with AGGRENOX and has a half-life of 0.33 hours. The half-life of salicylic acid is 1.71 hours. Both values correspond well with data from the literature at lower doses which state a resultant half-life of approximately 2–3 hours. At higher doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher. Renal excretion of unchanged drug depends upon urinary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from &lt;5% to &gt;80%. Alkalinization of the urine is a key concept in the management of salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> [<span class="Italics"><span class="Emphasis">see Overdosage <a href="#Section_10">(10)</a></span></span>]. Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, as the phenolic and acyl glucuronides, in urine.</p>
<p><span class="Underline"><span class="Emphasis">Special Populations</span></span><br><span class="Italics"><span class="Emphasis">Hepatic Dysfunction</span></span>: Avoid aspirin in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<p><span class="Italics"><span class="Emphasis">Renal Dysfunction</span></span>: Avoid aspirin in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (glomerular filtration rate less than 10 mL/min).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m<span class="Sup">2</span> basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats.</p>
<p>Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, <span class="Italics"><span class="Emphasis">in vivo</span></span> chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were negative.</p>
<p>Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and reproductive performance. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m<span class="Sup">2</span> basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m<span class="Sup">2</span> basis). Aspirin inhibits ovulation in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">ESPS2 (European <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Prevention Study 2) was a double-blind, placebo-controlled, 24-month study in which 6602 patients over the age of 18 years had an <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span> (76%) or transient ischemic attack (TIA, 24%) within three months prior to entry. Patients were enrolled in 13 European countries between February 1989 and May 1995 and were randomized to one of four treatment groups: AGGRENOX (aspirin/extended-release dipyridamole) 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone; aspirin (ASA) 25 mg alone; or placebo. The mean age in this population was 66.7 years with 58% of them being males. Patients received one capsule twice daily (morning and evening). Efficacy assessments included analyses of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (fatal or nonfatal) and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (from all causes) as confirmed by a blinded morbidity and mortality assessment group. There were no differences with regard to efficacy based on age or gender; patients who were older had a trend towards more events.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Endpoint</span></span><br>
								AGGRENOX reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 22.1% compared to aspirin 50 mg/day alone (p = 0.008) and reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 24.4% compared to extended-release dipyridamole 400 mg/day alone (p = 0.002) (Table 4). AGGRENOX reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by 36.8% compared to placebo (p &lt;0.001).</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4   Summary of First <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> (Fatal or Nonfatal): ESPS2: Intent-to-Treat Population</span></caption>
<col align="left" width="20%">
<col align="left">
<col align="left">
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<thead><tr class="First Last">
<th align="left"> </th>
<th align="left">Total<br>Number<br>of Patients<br>n</th>
<th align="left">Number of Patients<br>With<br><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Within 2 Years<br>n (%)</th>
<th align="left">Kaplan-Meier Estimate<br>of Survival at 2 Years<br>(95% C.I.)</th>
<th align="left">Gehan-Wilcoxon<br>Test<br>P-value</th>
<th align="left">Risk Reduction<br>at 2 Years</th>
<th align="left">Odds Ratio<br>(95% C.I.)</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">*0.010 &lt; p-value ≤0.050; **p-value ≤0.010.</td></tr>
<tr class="Last"><td align="left" colspan="7">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID</td></tr>
</tfoot>
<tbody>
<tr class="First"><td align="left" colspan="7"><span class="Bold"><span class="Emphasis">Individual Treatment<br>Group</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   AGGRENOX</td>
<td class="Toprule" align="left">1650</td>
<td class="Toprule" align="left">157 ( 9.5%)</td>
<td class="Toprule" align="left">89.9% (88.4%, 91.4%)</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
</tr>
<tr>
<td class="Toprule" align="left">   ER-DP</td>
<td class="Toprule" align="left">1654</td>
<td class="Toprule" align="left">211 (12.8%)</td>
<td class="Toprule" align="left">86.7% (85.0%, 88.4%)</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
</tr>
<tr>
<td class="Toprule" align="left">   ASA</td>
<td class="Toprule" align="left">1649</td>
<td class="Toprule" align="left">206 (12.5%)</td>
<td class="Toprule" align="left">87.1% (85.4%, 88.7%)</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
</tr>
<tr>
<td class="Toprule" align="left">   Placebo</td>
<td class="Toprule" align="left">1649</td>
<td class="Toprule" align="left">250 (15.2%)</td>
<td class="Toprule" align="left">84.1% (82.2%, 85.9%)</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
</tr>
<tr><td class="Toprule" align="left" colspan="7"><span class="Bold"><span class="Emphasis">Pairwise Treatment Group Comparisons</span></span></td></tr>
<tr>
<td class="Toprule" align="left">   AGGRENOX vs.<br>      ER-DP</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="center">0.002**</td>
<td class="Toprule" align="center">24.4%</td>
<td class="Toprule" align="center">0.72 (0.58, 0.90)</td>
</tr>
<tr>
<td class="Toprule" align="left">   AGGRENOX vs.<br>      ASA</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="center">0.008**</td>
<td class="Toprule" align="center">22.1%</td>
<td class="Toprule" align="center">0.74 (0.59, 0.92)</td>
</tr>
<tr>
<td class="Toprule" align="left">   AGGRENOX vs.<br>      Placebo</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="center">&lt;0.001**</td>
<td class="Toprule" align="center">36.8%</td>
<td class="Toprule" align="center">0.59 (0.48, 0.73)</td>
</tr>
<tr>
<td class="Toprule" align="left">   ER-DP vs.<br>      Placebo</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="center">0.036*</td>
<td class="Toprule" align="center">16.5%</td>
<td class="Toprule" align="center">0.82 (0.67, 1.00)</td>
</tr>
<tr class="Last">
<td class="Toprule" align="left">   ASA vs.<br>      Placebo</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="left">-</td>
<td class="Toprule" align="center">0.009**</td>
<td class="Toprule" align="center">18.9%</td>
<td class="Toprule" align="center">0.80 (0.66, 0.97)</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Emphasis">ESPS2: Cumulative <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> Rate (Fatal or Nonfatal)</span></span><br>
								Over 24 months of Follow-UP</p>
<div class="Figure"><img alt="Figure 1." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5&amp;name=aggrenox-figure1.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1.1"></a><a name="section-13.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Combined <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Endpoint</span></span><br>
										In ESPS2, AGGRENOX reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> by 12.1% compared to aspirin alone and by 10.3% compared to extended-release dipyridamole alone. These results were not statistically significant. AGGRENOX reduced the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> by 24.2% compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1.2"></a><a name="section-13.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Endpoint</span></span><br>
The incidence rate of all cause mortality was 11.3% for AGGRENOX, 11.0% for aspirin alone, 11.4% for extended-release dipyridamole alone and 12.3% for placebo alone. The differences between the AGGRENOX, aspirin alone and extended-release dipyridamole alone treatment groups were not statistically significant. These incidence rates for AGGRENOX and aspirin alone are consistent with previous aspirin studies in <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and TIA patients.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">AGGRENOX capsules are available as a hard gelatin capsule, with a red cap and an ivory-colored body, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".</p>
<p>AGGRENOX capsules are supplied in unit-of-use bottles of 60 capsules (<span class="Bold">NDC 54868-5143-0</span>).</p>
<br><p><br></p>
<p><br></p>
<p><span class="Bold"><span class="Emphasis">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)</span></span> [see USP Controlled Room Temperature]. Protect from excessive moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis">See FDA-approved Patient Labeling</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Inform patients that as with other antiplatelet agents, there is a general risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> including intracranial and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Inform patients about the signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including occult <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Tell patients to notify their physician if they are prescribed any drug which may increase risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Counsel patients who consume three or more alcoholic drinks daily about the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risks involved with chronic, heavy alcohol use while taking aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2  Pregnancy</h2>
<p class="First">Inform patients that aspirin is known to be harmful to fetuses and ask the patient to notify them if they are or become pregnant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3  Headaches</h2>
<p class="First">Some patients may experience <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> upon treatment initiation; these are usually transient. In case of intolerable <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, tell the patient to contact their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4  Dosage and Administration</h2>
<p class="First">Tell patients that AGGRENOX capsules should be swallowed whole, and not chewed or crushed. If you miss a dose, continue with your next dose on your regular schedule. Do not take a double dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5  Storage</h2>
<p class="First">Inform patients to protect AGGRENOX from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Distributed by:<br>
						Boehringer Ingelheim Pharmaceuticals, Inc.<br>
						Ridgefield, CT 06877 USA</p>
<p>Licensed from: <br>
						Boehringer Ingelheim International GmbH</p>
<p>Copyright 2011 Boehringer Ingelheim International GmbH<br>
						ALL RIGHTS RESERVED</p>
<p>OT1000HA062011<br>
						42633-09</p>
<p>IT5020B<br>
						73147-02</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma      74146<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Patient Information</span></span></p>
<p><span class="Bold"><span class="Emphasis">Aggrenox® (AG-reh-nox)</span></span><br><span class="Bold"><span class="Emphasis">(aspirin/extended-release dipyridamole)</span></span><br><span class="Bold"><span class="Emphasis">Capsules</span></span></p>
<p>Read this Patient Information before you start taking AGGRENOX and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold"><span class="Emphasis">What is AGGRENOX?</span></span></p>
<p>AGGRENOX is a prescription medicine that contains aspirin and a medicine that is slowly released in your body, called dipyridamole. AGGRENOX is used to lower the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in people who have had a "mini-<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>" (transient <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> attack or TIA) or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> due to a blood clot.</p>
<p>It is not known if AGGRENOX is safe and effective in children. See "Who should not take AGGRENOX?"</p>
<p><span class="Bold"><span class="Emphasis">Who should not take AGGRENOX?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Do not take AGGRENOX</span></span> if you:</p>
<ul class="Disc">
<li>are allergic to any of the ingredients in AGGRENOX. See the end of this leaflet for a list of ingredients in AGGRENOX.</li>
<li>are allergic to non-steroidal anti-inflammatory drugs (NSAIDS)</li>
<li>have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in combination with <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span></li>
</ul>
<p><span class="Bold"><span class="Emphasis">Do not give AGGRENOX to a child or teenager with a viral illness. Reye’s syndrome, a life-threatening condition, can happen when aspirin (an ingredient in AGGRENOX) is used in children and teenagers who have certain viral illnesses.</span></span></p>
<p><span class="Bold"><span class="Emphasis">What should I tell my doctor before using AGGRENOX?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Before taking AGGRENOX, tell your healthcare provider if you:</span></span></p>
<ul class="Disc">
<li>have <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have heart problems</li>
<li>have kidney or liver problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span></li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. AGGRENOX can harm your unborn baby, especially if you take it in the last (third) trimester of pregnancy. You should not take AGGRENOX during pregnancy without first talking to your healthcare provider. Tell your healthcare provider right away if you become pregnant while taking AGGRENOX.</li>
<li>are breast-feeding or plan to breast-feed. AGGRENOX can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take AGGRENOX.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Tell your doctor about all the medicines you take</span></span> including, prescription and non-prescription medicines, vitamins and herbal supplements. AGGRENOX and other medicines may affect each other causing side effects. AGGRENOX may affect the way other medicines work, and other medicines may affect how AGGRENOX works.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">a medicine for high blood pressure, irregular heart beat, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span></span></li>
<li><span class="Bold"><span class="Emphasis">acetazolamide [Diamox®]</span></span></li>
<li><span class="Bold"><span class="Emphasis">the blood thinner medicine warfarin sodium [Coumadin®, Jantoven®] or a heparin medicine</span></span></li>
<li><span class="Bold"><span class="Emphasis">a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine</span></span></li>
<li><span class="Bold"><span class="Emphasis">a medicine for Alzheimer’s disease</span></span></li>
<li><span class="Bold"><span class="Emphasis">a water pill</span></span></li>
<li><span class="Bold"><span class="Emphasis">methotrexate sodium [Trexall®]</span></span></li>
<li>
<span class="Bold"><span class="Emphasis">aspirin or a non-steroidal anti-inflammatory drug (NSAIDS). You should not take NSAIDS during treatment with AGGRENOX.</span></span> Using these medicines with AGGRENOX can increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li><span class="Bold"><span class="Emphasis">a medicine for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></span></span></li>
<li><span class="Bold"><span class="Emphasis">probenecid [Probalan®, Col-Probenecid®]</span></span></li>
</ul>
<p>Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above. </p>
<p>Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold"><span class="Emphasis">How should I take AGGRENOX?</span></span></p>
<ul class="Disc">
<li>Take AGGRENOX exactly as prescribed. Your healthcare provider will tell you how many AGGRENOX to take and when to take them.</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> are not uncommon when you first start taking AGGRENOX, but often lessen as treatment continues. Tell your healthcare provider if you have a severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Your healthcare provider may change the instructions for taking AGGRENOX.</li>
<li>Swallow AGGRENOX whole. Do not crush or chew the capsules.</li>
<li>You can take AGGRENOX with or without food.</li>
<li><span class="Bold Italics Underline"><span class="Emphasis">If you miss a dose, take your next dose at the usual time. Do not take two doses at one time.</span></span></li>
<li>If you take more AGGRENOX (<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>) than prescribed, call your healthcare provider or Poison Control Center, or get emergency help right away.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Symptoms of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of AGGRENOX include:</span></span></p>
<ul class="Disc">
<li>a warm feeling or <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>a fast heart rate</li>
<li>ringing in the ears </li>
</ul>
<p><span class="Bold"><span class="Emphasis">What should I avoid while using AGGRENOX?</span></span></p>
<ul class="Disc"><li>
<span class="Bold"><span class="Emphasis">heavy alcohol use.</span></span> People who drink three or more alcoholic drinks every day have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during treatment with AGGRENOX, because it contains aspirin.</li></ul>
<p><span class="Bold"><span class="Emphasis">What are the possible side effects of AGGRENOX?</span></span></p>
<p><span class="Bold"><span class="Emphasis">AGGRENOX may cause serious side effects, including:</span></span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</span></span> You may bleed more easily during AGGRENOX treatment, and it may take longer than usual for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop. This can include:
								<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> into your brain (<span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>).</span></span> This can be a medical emergency. Get medical help right away if you have any of these symptoms while taking AGGRENOX:
										<ul class="Square">
<li>severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or memory change</li>
<li>pass out (become <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>)</li>
</ul>
</li>
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your stomach or intestine.</span></span><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> blood or vomit looks like "coffee grounds"</li>
<li>red or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> that look like tar</li>
</ul>
</li>
</ul>
</li>
<li>
<span class="Bold"><span class="Emphasis">new or worsening <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> in some people with heart disease.</span></span> Tell your healthcare provider if you have new <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or have any change in your <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> during treatment with AGGRENOX.
								</li>
<li>
<span class="Bold"><span class="Emphasis">liver problems,</span></span> including increased liver function tests and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Tell your healthcare provider if you have any of these symptoms of a liver problem while taking AGGRENOX:
								<ul class="Disc">
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> colored stool</li>
<li>stomach area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>yellowing of your skin or whites of your eyes</li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </li>
</ul>
</li>
</ul>
<p>Call your healthcare provider right away if you have any of the symptoms listed above.</p>
<p><span class="Bold"><span class="Emphasis">The most common side effects of AGGRENOX include:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
</ul>
<p>These are not all the possible side effects of AGGRENOX. Tell your healthcare provider or pharmacist if you have any side effect that bothers you or that does not go away.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold"><span class="Emphasis">How should I store AGGRENOX?</span></span></p>
<ul class="Disc">
<li>Store AGGRENOX at 59°F to 86°F (15°C to 30°C).</li>
<li>Keep AGGRENOX capsules dry.</li>
<li>Safely throw away medicine that is out of date or no longer needed.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Keep AGGRENOX and all medicines out of the reach of children.</span></span></p>
<p><span class="Bold"><span class="Emphasis">General information about AGGRENOX</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not use AGGRENOX for a condition for which it was not prescribed. Do not give AGGRENOX to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Patient Information summarizes the most important information about AGGRENOX. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about AGGRENOX that is written for health professionals. For more information, call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.</p>
<p><span class="Bold"><span class="Emphasis">What are the ingredients in AGGRENOX?</span></span></p>
<p>Active Ingredients: dipyridamole in an extended-release form and aspirin<br>
Inactive Ingredients: acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide and triacetin.  Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide, and water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_20"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Distributed by:<br>
						Boehringer Ingelheim Pharmaceuticals, Inc.<br>
						Ridgefield, CT 06877 USA</p>
<p>Licensed from:<br> 
						Boehringer Ingelheim International GmbH</p>
<p>Copyright 2011 Boehringer Ingelheim International GmbH<br>
						ALL RIGHTS RESERVED</p>
<p>Revised: January 2011</p>
<p>OT1000HA062011<br>
						42633-09</p>
<p>IT5020B<br>
						73147-02</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_23"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First">Aggrenox</p>
<p>25 mg/200 mg capsules</p>
<p>60 Capsules</p>
<p>NDC 54868-5143-0</p>
<div class="Figure"><img alt="Aggrenox - 60 capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e729d829-4bd0-4074-85ea-e0f9f5d7cdb5&amp;name=5143.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AGGRENOX 		
					</strong><br><span class="contentTableReg">aspirin and dipyridamole capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5143(NDC:0597-0001)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>aspirin</strong> (aspirin) </td>
<td class="formItem">aspirin</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>dipyridamole</strong> (dipyridamole) </td>
<td class="formItem">dipyridamole</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromellose phthalate (31% phthalate, 170 cst)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methacrylic acid - methyl methacrylate copolymer (1:1)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red) , WHITE (ivory) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">24mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">01A;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5143-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020884</td>
<td class="formItem">08/24/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37a9009f-2b28-49bc-9ca7-47193bb56554</div>
<div>Set id: e729d829-4bd0-4074-85ea-e0f9f5d7cdb5</div>
<div>Version: 2</div>
<div>Effective Time: 20120416</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
